Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

OUEST PHARMA HOLDING : revenue, balance sheet and financial ratios

OUEST PHARMA HOLDING is a French company founded 4 years ago, specialized in the sector Autres intermédiaires du commerce en produits divers. Based in MEZIERES-LEZ-CLERY (45370), this company of category PME shows in 2024 a net income positive of 275 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - OUEST PHARMA HOLDING (SIREN 901564062)
Kennzahl 2024 2023 2022 2021
Umsatz N/C N/C N/C N/C
Nettoergebnis 275 358 € 106 743 € 93 026 € -50 €
EBITDA -1 595 € -6 489 € -989 € -50 €
Nettomarge N/C N/C N/C N/C

Umsatz und Gewinn- und Verlustrechnung

In 2024, OUEST PHARMA HOLDING generates positive net income of 275 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2024) ?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit

-1 595 €

EBIT (2024) ?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen

-1 595 €

Nettoergebnis (2024) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

275 358 €

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 5%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.

Verschuldungsgrad (2024) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

4.592%

Finanzielle Autonomie (2024) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

93.423%

Rückzahlungsfähigkeit (2024) ?
Rückzahlungsfähigkeit
Definition
Anzahl der Jahre zur Schuldenrückzahlung mit dem Cashflow.
Formel
Dettes financières / CAF
Interpretation
< 3 Jahre : Ausgezeichnet
3-5 Jahre : Angemessen
> 5 Jahre : Attention

0.127

Entwicklung der Solvenzkennzahlen
OUEST PHARMA HOLDING

Positionnement sectoriel

Debt ratio
4.59 2024
2022
2023
2024
Q1: 0.0
Méd: 6.15
Q3: 45.95
Good -7 pts über 3 Jahre

In 2024, the debt ratio of OUEST PHARMA HOLDING (4.59) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
93.42% 2024
2022
2023
2024
Q1: 3.97%
Méd: 34.0%
Q3: 67.32%
Excellent

In 2024, the financial autonomy of OUEST PHARMA HOLDING (93.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.13 years 2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.0 years
Q3: 0.8 years
Average

In 2024, the repayment capacity of OUEST PHARMA HOLDING (0.13) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 1703.83. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquiditätsquote (2024) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

1703.826

Zinsdeckung (2024) ?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Formel
EBIT / Zinsaufwendungen
Interpretation
> 3 : Komfortabel
1.5-3 : Acceptable
< 1.5 : Risiko

-48.276

Entwicklung der Liquiditätskennzahlen
OUEST PHARMA HOLDING

Positionnement sectoriel

Liquidity ratio
1703.83 2024
2022
2023
2024
Q1: 139.4
Méd: 252.5
Q3: 584.37
Excellent

In 2024, the liquidity ratio of OUEST PHARMA HOLDING (1703.83) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-48.28x 2024
2022
2023
2024
Q1: 0.0x
Méd: 0.0x
Q3: 0.95x
Watch

In 2024, the interest coverage of OUEST PHARMA HOLDING (-48.3x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Umlaufvermögensbedarf und Zahlungsfristen

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 587 days. Excellent situation: suppliers finance 587 days of the operating cycle (retail model).

Operatives Working Capital (2024) ?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Formel
Stocks + Créances clients - Dettes fournisseurs
Interpretation
Negativ = freigesetzte Liquidität
Positiv = Finanzierungsbedarf

0 €

Kundenforderungen (2024) ?
Kundenforderungen (Tage)
Definition
Durchschnittliche Zahlungsfrist für Kunden.
Formel
(Kundenforderungen / Umsatz inkl. MwSt.) x 360
Interpretation
< 45j : Gut
45-60j : Durchschnitt
> 60j : Lang

0 j

Lieferantenverbindlichkeiten (2024) ?
Lieferantenverbindlichkeiten (Tage)
Definition
Durchschnittliche Zahlungsfrist von Lieferanten.
Formel
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität

587 j

Lagerumschlag (2024) ?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag

0 j

Entwicklung des Working Capital und der Zahlungsfristen
OUEST PHARMA HOLDING

Positionnement de OUEST PHARMA HOLDING dans son secteur

Vergleich mit der Branche Autres intermédiaires du commerce en produits divers

Bewertungsschätzung

Based on 85 transactions of similar company sales (all years), the value of OUEST PHARMA HOLDING is estimated at 378 082 € (range 180 278€ - 1 938 498€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
85 tx
180k€ 378k€ 1938k€
378 082 € Range: 180 278€ - 1 938 498€
NAF 5 all-time

Valuation method used

Net Income Multiple
275 358 € × 1.4x = 378 083 €
Range: 180 279€ - 1 938 498€

Only this financial indicator is available for this company.

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Autres intermédiaires du commerce en produits divers)

Compare OUEST PHARMA HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Autres intermédiaires du commerce en produits divers

Frequently asked questions about OUEST PHARMA HOLDING

What is the revenue of OUEST PHARMA HOLDING ?

The revenue of OUEST PHARMA HOLDING is not publicly disclosed (confidential accounts filed with INPI).

Is OUEST PHARMA HOLDING profitable?

Yes, OUEST PHARMA HOLDING generated a net profit of 275 k€ in 2024.

Where is the headquarters of OUEST PHARMA HOLDING ?

The headquarters of OUEST PHARMA HOLDING is located in MEZIERES-LEZ-CLERY (45370), in the department Loiret.

Where to find the tax return of OUEST PHARMA HOLDING ?

The tax return of OUEST PHARMA HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does OUEST PHARMA HOLDING operate?

OUEST PHARMA HOLDING operates in the sector Autres intermédiaires du commerce en produits divers (NAF code 46.19B). See the 'Sector positioning' section above to compare the company with its competitors.